Jacksonville, Florida 32224

  • 19


This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with the primary objective to compare the proportion of participants alive and respiratory failure free between CPI-006 plus SOC versus placebo plus SOC.


Inclusion Criteria: - Confirmed positive by polymerase chain reaction (PCR) or antigen test for SARS-CoV-2 with sample collection ≤ 10 days prior to randomization - Covid-19 illness of any duration of symptoms - Hospitalized for Covid-19 for ≤ 5 days with mild to moderate Covid-19 symptoms and meets criteria for either Category 4, Category 5, or Category 6 per 8-point ordinal scale - Adequate organ function - Participants of child-bearing age must agree to use adequate contraception for 6 weeks after study treatment administration Exclusion Criteria: - Signs of acute respiratory distress syndrome or respiratory failure necessitating mechanical ventilation at time of screening/randomization or anticipated need for mechanical ventilation - History of severe chronic respiratory disease and requirement for long-term oxygen therapy - Uncontrolled active systemic infection or hemodynamic instability requiring admission to an intensive care unit - Malignant tumor receiving treatment, or other serious systemic diseases affecting life expectancy within 29 days of screening - Receipt of cancer chemotherapy or immunomodulatory drugs during preceding 2 months (steroids for treatment of Covid-19 are acceptable) - Convalescent plasma (CCP) or anti-SARS-CoV-2 monoclonal antibodies administered <24 hours prior to randomization. Must have recovered from any adverse events related to CCP treatment. Received chloroquine or hydroxychloroquine within last 7 days or during the study - Current participation in other clinical trials including extended access programs - Active deep vein thrombosis or pulmonary embolism within last 6 months - Anticipated discharge from hospital or transfer to another hospital which is not a study site within 48 hours of admission - Active uncontrolled co-morbid disease that may interfere with study conduct or interpretation of findings - Known to be positive for HIV or positive test for chronic HBV infection or positive test for hepatitis C antibody - Pregnancy or breast feeding



Primary Contact:

Study Chair
S. Mahabhashyam, MD, MPH
Corvus Pharmaceuticals

Corvus Clinical Trials
Phone: 650-900-4520
Email: clinicaltrials@corvuspharma.com

Backup Contact:


Location Contact:

Jacksonville, Florida 32224
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: August 01, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.